VH3 antibody response to immunization with pneumococcal polysaccharide vaccine in middle-aged and elderly persons

Clinical and Vaccine Immunology

Volumn 18, Issue 3, 2011, Pages 362-366

  Serpa, Jose A ^a   Valayam, Josemon ^a,b   Musher, Daniel M ^a,b   Rossen, Roger D ^a   Pirofski, Liise Anne ^c   Rodriguez Barradas, Maria C ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IDIOTYPIC ANTIBODY; IMMUNOGLOBULIN G; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG; VARIABLE REGION HEAVY CHAIN FAMILY 3 ANTIBODY;

ADULT; AGED; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; MIDDLE AGED; NONHUMAN; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; REVACCINATION; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

AGED; AGED, 80 AND OVER; ANTIBODIES, BACTERIAL; HUMANS; IMMUNOGLOBULIN G; MIDDLE AGED; PNEUMOCOCCAL VACCINES;

EID: 79952542637     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00408-10     Document Type: Article

References (39)

1. Abadi, J., et al. 1998. Human antibodies elicited by a pneumococcal vaccine express idiotypic determinants indicative of V(H)3 gene segment usage. J. Infect. Dis. 178:707-716.
2. Artz, A. S., W. B. Ershler, and D. L. Longo. 2003. Pneumococcal vaccination and revaccination of older adults. Clin. Microbiol. Rev. 16:308-318.
3. Baxendale, H. E., and D. Goldblatt. 2006. Correlation of molecular characteristics, isotype, and in vitro functional activity of human antipneumococcal monoclonal antibodies. Infect. Immun. 74:1025-1031.
4. Carson, P. J., K. L. Nichol, J. O'Brien, P. Hilo, and E. N. Janoff. 2000. Immune function and vaccine responses in healthy advanced elderly patients. Arch. Intern. Med. 160:2017-2024.
5. Casadevall, A., and L. A. Pirofski. 2004. New concepts in antibody-mediated immunity. Infect. Immun. 72:6191-6196.
6. CDC. 2002. Recommended adult immunization schedule - United States, 2002-2003. MMWR Morb. Mortal. Wkly. Rep. 51:904-908.
7. Chang, Q., J. Abadi, P. Alpert, and L. Pirofski. 2000. A pneumococcal capsular polysaccharide vaccine induces a repertoire shift with increased VH3 expression in peripheral B cells from human immunodeficiency virus (HIV)-uninfected but not HIV-infected persons. J. Infect. Dis. 181:1313-1321.
8. Fedson, D. S., and D. M. Musher. 2004. Pneumococcal polysaccharide vaccine, p. 589-624. In S. A. Plotkin, W. A. Orenstein, and P. A. Offit (ed.), Vaccines. Elsevier, Philadelphia, PA.
9. González-Fernández, A., J. Faro, and C. Fernández. 2008. Immune responses to polysaccharides: lessons from humans and mice. Vaccine 26:292-300.
10. Jackson, L. A., et al. 1999. Safety of revaccination with pneumococcal polysaccharide vaccine. JAMA 281:243-248. (Pubitemid 29058113)
11. Kolibab, K., S. L. Smithson, B. Rabquer, S. Khuder, and M. A. Westerink. 2005. Immune response to pneumococcal polysaccharides 4 and 14 in elderly and young adults: analysis of the variable heavy chain repertoire. Infect. Immun. 73:7465-7476.
12. Kolibab, K., et al. 2005. Immune response to pneumococcal polysaccharides 4 and 14 in elderly and young adults. I. Antibody concentrations, avidity and functional activity. Immun. Ageing 2:10.
13. Lackner, T. E., et al. 2003. Pneumococcal polysaccharide revaccination: immunoglobulin G seroconversion, persistence, and safety in frail, chronically ill older subjects. J. Am. Geriatr. Soc. 51:240-245.
14. Manoff, S. B., et al. 2010. Revaccination with a 23-valent pneumococcal polysaccharide vaccine induces elevated and persistent functional antibody responses in adults aged 65 > or = years. J. Infect. Dis. 201:525-533.
15. Moberley, S. A., J. Holden, D. P. Tatham, and R. M. Andrews. 2008. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst. Rev. 2008:CD000422.
16. Mufson, M. A., D. F. Hughey, C. E. Turner, and G. Schiffman. 1991. Revaccination with pneumococcal vaccine of elderly persons 6 years after primary vaccination. Vaccine 9:403-407.
17. Musher, D. M., J. E. Groover, E. A. Graviss, and R. E. Baughn. 1996. The lack of association between aging and postvaccination levels of IgG antibody to capsular polysaccharides of Streptococcus pneumoniae. Clin. Infect. Dis. 22:165-167.
18. Musher, D. M., et al. 1993. Antibody to capsular polysaccharides of Streptococcus pneumoniae: prevalence, persistence, and response to revaccination. Clin. Infect. Dis. 17:66-73.
19. Musher, D. M., et al. 2010. Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults. J. Infect. Dis. 201:516-524.
20. Musher, D. M., H. M. Phan, D. A. Watson, and R. E. Baughn. 2000. Antibody to capsular polysaccharide of Streptococcus pneumoniae at the time of hospital admission for pneumococcal pneumonia. J. Infect. Dis. 182:158-167.
21. O'Brien, K. L., M. Hochman, and D. Goldblatt. 2007. Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue? Lancet Infect. Dis. 7:597-606. (Pubitemid 47268225)
22. Pandey, J. P. 2000. Immunoglobulin GM and KM allotypes and vaccine immunity. Vaccine 19:613-617.
23. Ridda, I., et al. 2009. Immunological responses to pneumococcal vaccine in frail older people. Vaccine 27:1628-1636.
24. Rodriguez-Barradas, M. C., et al. 1996. IgG antibody to pneumococcal capsular polysaccharide in human immunodeficiency virus-infected subjects: persistence of antibody in responders, revaccination in nonresponders, and relationship of immunoglobulin allotype to response. J. Infect. Dis. 173:1347-1353.
25. Romero-Steiner, S., et al. 1999. Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. Clin. Infect. Dis. 29:281-288.
26. Ruben, F. L., and M. Uhrin. 1985. Specific immunoglobulin-class antibody responses in the elderly before and after 14-valent pneumococcal vaccine. J. Infect. Dis. 151:845-849.
27. Sankilampi, U., P. O. Honkanen, A. Bloigu, E. Herva, and M. Leinonen. 1996. Antibody response to pneumococcal capsular polysaccharide vaccine in the elderly. J. Infect. Dis. 173:387-393.
28. Sankilampi, U., P. O. Honkanen, A. Bloigu, and M. Leinonen. 1997. Persistence of antibodies to pneumococcal capsular polysaccharide vaccine in the elderly. J. Infect. Dis. 176:1100-1104.
29. Shapiro, E. D., et al. 1991. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N. Engl. J. Med. 325:1453-1460.
30. Smithson, S. L., N. Srivastava, and M. A. Westerink. 2002. Differential V gene expression detected in the immune response to Streptococcus pneumoniae capsular polysaccharide between elderly and young adults. Hybrid Hybridomics 21:19-24.
31. Stein, K. E. 1992. Thymus-independent and thymus-dependent responses to polysaccharide antigens. J. Infect. Dis. 165(Suppl. 1):S49-S52.
32. Subramaniam, K. S., R. Segal, R. H. Lyles, M. C. Rodriguez-Barradas, and L. A. Pirofski. 2003. Qualitative change in antibody responses of human immunodeficiency virus-infected individuals to pneumococcal capsular polysaccharide vaccination associated with highly active antiretroviral therapy. J. Infect. Dis. 187:758-768.
33. Sun, Y., et al. 1999. Repertoire of human antibodies against the polysaccharide capsule of Streptococcus pneumoniae serotype 6B. Infect. Immun. 67:1172-1179.
34. Torling, J., J. Hedlund, H. B. Konradsen, and A. Ortqvist. 2003. Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middleaged and elderly persons previously treated for pneumonia. Vaccine 22:96-103. (Pubitemid 37357156)
35. Wang, X., and B. D. Stollar. 1999. Immunoglobulin VH gene expression in human aging. Clin. Immunol. 93:132-142.
36. Wernette, C. M., et al. 2003. Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. Clin. Diagn. Lab. Immunol. 10:514-519.
37. Whitney, C. G., et al. 2003. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N. Engl. J. Med. 348:1737-1746.
38. Zhong, Z., T. Burns, Q. Chang, M. Carroll, and L. Pirofski. 1999. Molecular and functional characteristics of a protective human monoclonal antibody to serotype 8 Streptococcus pneumoniae capsular polysaccharide. Infect. Immun. 67:4119-4127.
39. Zhou, J., K. R. Lottenbach, S. J. Barenkamp, A. H. Lucas, and D. C. Reason. 2002. Recurrent variable region gene usage and somatic mutation in the human antibody response to the capsular polysaccharide of Streptococcus pneumoniae type 23F. Infect. Immun. 70:4083-4091.